trending Market Intelligence /marketintelligence/en/news-insights/trending/JcWKEQr_rw7CLPjcYCDQAQ2 content esgSubNav
In This List

Cellectar Biosciences receives patent protection for cancer drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Cellectar Biosciences receives patent protection for cancer drug

Cellectar Biosciences Inc. received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers as well as associated cancer stem cells.

The patent protection will last through the end of 2035.